Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Low dose of telmisartan (Drug); High dose of telmisartan (Drug); Low dose of losartan (Drug); High dose of losartan (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the
treatment of the mild to moderate primary hypertension patients in China
Clinical Details
Official title: 12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Changes in mean sitting valley value of DBP
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood
pressure (DBP) ≥ 95 and < 110 mmHg, and the mean sitting valley value of systolic blood
pressure (SBP) < 180 mmHg
Exclusion Criteria:
- Not specified
Locations and Contacts
Additional Information
Starting date: July 2000
Last updated: October 20, 2014
|